Review the University of Kansas Medical Center's clinical experience using ravulizumab and efgartigimod alpha-fcab for patients with myasthenia gravis.   

Ravulizumab and efgartigmod alpha-fcab are two recently approved medications for the treatment of myasthenia gravis. Though they have been proven to be safe and effective, little has been published since their releases regarding clinicians’ experiences with these medications.

After IRB approval was obtained, we performed a retrospective chart review of patients with myasthenia gravis from a single academic center who had received at least one infusion of ravulizumab or efgartigimod alpha-fcab. Demographic, clinical, and therapeutic information was obtained from the charts. Descriptive analysis will be performed on the data obtained.  

Seventeen patients have been prescribed either ravulizumab or efgartigimod. Eleven patients are waiting for approval or infusion scheduling, five have received their first infusion and are scheduled for follow-up in clinic. Two patients had completed their first infusions of ravulizumab and had follow-up data. The study is ongoing with hopes to have data from 25-50 patients in the coming months.  

The study is presently ongoing.